Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

NCT06106581 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT06106581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06106581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years
Lead sponsor
Valneva Austria GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2023
Completion date
July 2, 2025
Enrollment
304 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection